Patient Surveillance After Cancer TreatmentFrank E Johnson, Yoshihiko Maehara, George P Browman, Julie A. Margenthaler, Riccardo A. Audisio, John F Thompson, David Y. Johnson, Craig C. Earle, Katherine S. Virgo Springer Science & Business Media, 12 mar 2013 - 538 Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer. The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients. This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist. |
Spis treści
2 | |
2 Introduction to Cancer Surveillance Strategies | 9 |
3 Using Decision Analysis to Model Cancer Surveillance | 14 |
4 Cancer Survivorship Monitoring the LongTerm and Late Effects of Treatment | 31 |
5 Upper Aerodigestive Tract Carcinoma | 38 |
6 Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint Europe | 43 |
7 Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint Japan | 46 |
8 Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint Canada | 51 |
55 Breast Carcinoma Surveillance Counterpoint Europe | 281 |
56 Breast Carcinoma Surveillance Counterpoint Australia | 284 |
57 Breast Carcinoma Surveillance Counterpoint Japan | 293 |
58 Endometrial Carcinoma | 296 |
59 Endometrial Cancer Surveillance Counterpoint USA | 301 |
60 Endometrial Cancer Surveillance Counterpoint USA | 305 |
61 Carcinoma of the Endometrium Surveillance Counterpoint Japan | 311 |
62 Endometrial Carcinoma Surveillance Counterpoint Canada | 317 |
9 Thyroid Papillary Follicular Medullary Hürthle Cell Carcinoma | 57 |
10 Thyroid Papillary Follicular Medullary Hürthle Cell Carcinoma Surveillance Counterpoint Australia | 62 |
11 Thyroid Papillary Follicular Medullary Hürthle Cell Carcinoma Surveillance Counterpoint Japan | 69 |
12 Lung Carcinoma | 71 |
13 Lung Carcinoma Surveillance Counterpoint Australia | 75 |
14 Lung Carcinoma Surveillance Counterpoint Japan | 79 |
15 Lung Carcinoma Surveillance Counterpoint Canada | 83 |
16 Esophagus Carcinoma | 93 |
17 Esophagus Carcinoma Surveillance Counterpoint Australia | 96 |
18 Esophagus Carcinoma Surveillance Counterpoint Japan | 101 |
19 Stomach | 107 |
20 Stomach Carcinoma Surveillance Counterpoint USA | 109 |
21 Stomach Carcinoma Surveillance Counterpoint Japan | 113 |
22 Pancreatic Adenocarcinoma | 120 |
23 Pancreatic Adenocarcinoma Surveillance Counterpoint USA | 125 |
24 Pancreatic Adenocarcinoma Surveillance Counterpoint Europe | 128 |
25 Pancreatic Adenocarcinoma Surveillance Counterpoint Japan | 145 |
26 Pancreatic Adenocarcinoma Surveillance Counterpoint Canada | 148 |
27 Liver and Biliary Tract Carcinoma | 153 |
28 Liver and Biliary Tract Carcinoma Surveillance Counterpoint Europe | 156 |
29 Liver and Biliary Tract Carcinoma Surveillance Counterpoint Australia | 159 |
30 Liver and Biliary Tract Carcinoma Surveillance Counterpoint Japan | 165 |
31 Liver and Biliary Tract Carcinoma Surveillance Counterpoint Canada | 168 |
32 Colon and Rectum Carcinoma | 179 |
33 Colon and Rectum Carcinoma Surveillance Counterpoint USA | 185 |
34 Colon and Rectum Carcinoma Surveillance Counterpoint Australia | 188 |
35 Colon and Rectum Carcinoma Surveillance Counterpoint Japan | 195 |
36 Colon and Rectum Carcinoma Surveillance Counterpoint Canada | 199 |
37 Anal Carcinoma | 205 |
38 Anal Carcinoma Surveillance Counterpoint USA | 207 |
39 Anal Carcinoma Surveillance Counterpoint Australia | 215 |
40 Anal Carcinoma Surveillance Counterpoint Japan | 219 |
41 Anal Carcinoma Surveillance Counterpoint Canada | 222 |
42 Soft Tissue Sarcoma | 227 |
43 Soft Tissue Sarcoma Surveillance Counterpoint USA | 231 |
44 SoftTissue Sarcoma Surveillance Counterpoint Japan | 233 |
45 Soft Tissue Sarcoma Surveillance Counterpoint Canada | 235 |
46 Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma | 242 |
47 Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint Japan | 247 |
48 Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint Canada | 249 |
49 Cutaneous Melanoma | 251 |
50 Cutaneous Melanoma Surveillance Counterpoint USA | 254 |
51 Cutaneous Melanoma Surveillance Counterpoint Australia | 265 |
52 Cutaneous Melanoma Surveillance Counterpoint Japan | 269 |
53 Breast Carcinoma | 273 |
54 Breast Carcinoma Surveillance Counterpoint USA | 277 |
63 Cervical Carcinoma | 323 |
64 Cervical Carcinoma Surveillance Counterpoint USA | 326 |
65 Cervical Carcinoma Surveillance Counterpoint Japan | 335 |
66 Cervical Carcinoma Surveillance Counterpoint Canada | 341 |
67 Vaginal and Vulvar Carcinoma | 348 |
68 Vaginal and Vulvar Carcinoma Surveillance Counterpoint Japan | 353 |
69 Ovarian Carcinoma | 356 |
70 Ovarian Carcinoma Surveillance Counterpoint USA | 361 |
71 Ovarian Cancer Surveillance Counterpoint Europe | 365 |
72 Ovarian Cancer Surveillance Counterpoint Japan | 368 |
73 Renal Carcinoma | 373 |
74 Renal Carcinoma Surveillance Counterpoint Europe | 375 |
75 Renal Carcinoma Surveillance Counterpoint Japan | 380 |
76 Renal Carcinoma Surveillance Counterpoint Canada | 383 |
77 Urinary Bladder Carcinoma | 387 |
78 Urinary Bladder Carcinoma Surveillance Counterpoint Japan | 392 |
79 Urinary Bladder Carcinoma Surveillance Counterpoint Canada | 395 |
80 Prostate Carcinoma | 399 |
81 Prostate Carcinoma Surveillance Counterpoint USA | 403 |
82 Prostate Cancer Surveillance Counterpoint USA | 411 |
83 Prostate Carcinoma Surveillance Counterpoint Europe | 421 |
84 Prostate Carcinoma Surveillance Counterpoint Japan | 423 |
85 Prostate Carcinoma Surveillance Counterpoint Canada | 426 |
86 Testicle Carcinoma | 437 |
87 Testicle Carcinoma Surveillance Counterpoint USA | 442 |
88 Testicle Carcinoma Surveillance Counterpoint Australia | 449 |
89 Testicle Carcinoma Surveillance Counterpoint Japan | 453 |
90 Lymphoma | 456 |
91 Lymphoma Surveillance Counterpoint USA | 461 |
92 Lymphoma Surveillance Counterpoint Japan | 467 |
93 Lymphoma Following Autologous Stem Cell Transplant | 469 |
94 Lymphoma Following Autologous Stem Cell Transplant Surveillance Counterpoint Japan | 471 |
95 Leukemia | 475 |
96 Leukemia Surveillance Counterpoint USA | 478 |
97 Leukemia Surveillance Counterpoint Japan | 485 |
98 Multiple Myeloma | 487 |
99 Multiple Myeloma Surveillance Counterpoint USA | 489 |
100 Multiple Myeloma Surveillance Counterpoint Australia | 493 |
101 Multiple Myeloma Surveillance Counterpoint Japan | 501 |
102 Multiple Myeloma Surveillance Counterpoint Canada | 503 |
103 Glioma of the Central Nervous System | 510 |
104 Glioma of the Central Nervous System Surveillance Counterpoint Europe | 515 |
105 Glioma of the Central Nervous System Surveillance Counterpoint Australia | 517 |
106 Glioma of the Central Nervous System Surveillance Counterpoint Japan | 520 |
525 | |